Rilematovir

Generic Name
Rilematovir
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C21H20ClF3N4O3S
CAS Number
1383450-81-4
Unique Ingredient Identifier
NQ99E8OH3P
Background

Rilematovir is under investigation in clinical trial NCT04056611 (Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV)).

Associated Conditions
-
Associated Therapies
-

A Study in Healthy Adult Participants to Assess the Effects of Ciclosporin Administration on Rilematovir

Phase 1
Completed
Conditions
Interventions
First Posted Date
2021-12-13
Last Posted Date
2022-02-17
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
18
Registration Number
NCT05155007
Locations
🇧🇪

Clinical Pharmacology Unit, Merksem, Belgium

A Study of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2021-07-27
Last Posted Date
2023-04-21
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
5
Registration Number
NCT04978337
Locations
🇺🇸

Pines Care Research Center Inc, Pembroke Pines, Florida, United States

🇺🇸

Renovatio Clinical, The Woodlands, Texas, United States

🇺🇸

Frontier Clinical Research, Morgantown, West Virginia, United States

and more 81 locations

A Study of Rilematovir in Infants and Children and Subsequently in Neonates Hospitalized With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus (RSV)

First Posted Date
2020-10-12
Last Posted Date
2024-03-01
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
28
Registration Number
NCT04583280
Locations
🇧🇪

UZ Leuven, Leuven, Belgium

🇧🇬

Acibadem City Clinic Tokuda Hospital, Sofia, Bulgaria

🇭🇺

Petz Aladar Megyei Oktato Korhaz, Győr, Hungary

and more 139 locations
© Copyright 2024. All Rights Reserved by MedPath